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MutT Homolog 1 Inhibitor Karonudib 
Attenuates Autoimmune Hepatitis by 
Inhibiting DNA Repair in Activated 
T Cells
Yong Chen,1* Xiangwei Hua,2-4* Bingyuan Huang,1* Stella Karsten ,3 Zhengrui You,1 Bo Li,1 You Li,1 Yikang Li,1 Jubo Liang,1 
Jun Zhang,1 Yiran Wei,1 Ruiling Chen,1 Zhuwan Lyu ,1 Xiao Xiao,1 Min Lian,1 Jue Wei,5 Jingyuan Fang,1 Qi Miao,1  
Qixia Wang,1 Ulrika Warpman Berglung,3 Ruqi Tang,1** Thomas Helleday,3,6** and Xiong Ma 1**
Autoimmune hepatitis (AIH) is an inflammatory liver disease driven by the hyperactivation of various intrahepatic 
antigen- specific T cells due to a breach of immune tolerance. Studies in immunometabolism demonstrate that activated 
T cells harbor increased levels of reactive oxygen species that cause oxidative DNA damage. In this study, we assessed 
the potential of DNA damage repair enzyme MutT homolog 1 (MTH1) as a therapeutic target in AIH and karonudib 
as a novel drug for patients with AIH. We report herein that MTH1 expression was significantly increased in liver 
samples from patients with AIH compared to patients with chronic hepatitis B and nonalcoholic fatty liver disease 
and from healthy controls. In addition, the expression of MTH1 was positively correlated with AIH disease severity. 
We further found abundant T cells that expressed MTH1 in AIH. Next, we found that karonudib significantly altered 
T- cell receptor signaling in human T cells and robustly inhibited proliferation of human T cells in vitro. Interestingly, 
our data reflected a preferential inhibition of DNA damage repair in activated T cells by karonudib. Moreover, MTH1 
was required to develop liver inflammation and damage because specific deletion  of MTH1 in T cells ameliorated liver 
injury  in the concanavalin A (Con A)- induced hepatitis model  by inhibiting T- cell activation and proliferation. Lastly, 
we validated the protective effect of karonudib on the Con A- induced hepatitis model. Conclusion: MTH1 functions as 
a critical regulator in the development of AIH, and its inhibition in activated T cells reduces liver inflammation and 
damage. (Hepatology Communications 2021;0:1-16).
A
utoimmune hepatitis (AIH) is an inflamma-
tory liver disease characterized by elevated 
levels of serum transaminase and immu-
noglobulin G, the presence of autoantibodies (such 
as antinuclear antibodies), the existence of interface 
hepatitis, and portal plasma cell infiltration in liver 
histology.(1) Strong evidence suggests that AIH is 
driven by the expansion of various antigen- specific 
T cells due to a breach of immune tolerance.(2) The 
mainstay for AIH treatment is the recommendation 
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of predniso(lo)ne to induce remission and the combi-
nation of predniso(lo)ne and azathioprine to maintain 
therapeutic efficacy.(3) Although different medicines 
have been developed to treat AIH, adverse effects 
are a limitation, e.g., predniso(lo)ne causes osteopo-
rosis(4) and exacerbates diabetes(5) and azathioprine 
brings hematologic abnormalities, such as leukope-
nia(6) and myelodysplastic syndromes.(7) In addition, 
many patients do not respond to these medicines.(8) 
Therefore, it is imperative to develop new and more 
effective immunosuppressive drugs.
T cells are the critical immune cells that fight 
against pathogens, protecting the immune homeosta-
sis in physiologic conditions. However, the aberrantly 
activated T cells could secret robust proinflammatory 
cytokines, causing injury to normal tissues and leading 
to inflammatory or autoimmune diseases. To facilitate 
the full- effector status, these immune cells alter their 
metabolic pattern that accompanies the overwhelming 
amounts of reactive oxygen species (ROS) produc-
tion.(9) Existing studies consider DNA damage as one 
of the major outcomes of ROS overproduction.(10,11) 
The nucleotides present in the nucleotide pool are 
more susceptible to oxidative damage than those in 
the DNA strands.(12) Among them, guanine has 
the lowest redox potential and the deoxyguano-
sine triphosphate (dGTP) pool is the most vulnera-
ble target for oxidation, leading to the formation of 
8- oxo- 7,8- dihydroguanine (8- oxoG).(13)
MutT homolog 1 (MTH1) is an enzyme belong-
ing to the nucleotide diphosphate X phosphohydro-
lase family. The main role of MTH1 is to hydrolyze 
8- oxo- dGTP to 8- oxo- deoxyguanosine monophos-
phate (dGMP), which prevents the misincorpora-
tion of the former into DNA.(14,15) Previous studies 
showed that MTH1 expression was elevated in tumor 
cells and was correlated with prognosis and sur-
vival.(16,17) Studies have shown that a prerequisite to 
successful elimination of cancer using MTH1 inhib-
itor is the misincorporation of oxidized nucleotides 
into DNA.(18,19) Currently, a clinical trial is under-
way to verify whether the MTH1 inhibitor karonu-
dib is effective in the treatment of cancer in humans 
(NCT03036228).
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Given that hyperactive T cells and cancer cells are 
both rapid proliferating cells and have a similar meta-
bolic pattern, we explored the potential role of MTH1 
in the pathogenesis of AIH. We first investigated 
expression levels of MTH1 in T cells of liver tissues 
of patients with AIH. Next, we assessed the effects 
of karonudib on human T cells in vitro. Lastly, we 
examined the role of MTH1 on concanavalin A (Con 
A)- induced liver injury using mice with the specific 
deletion of MTH1 in T cells and the novel MTH1 
inhibitor karonudib in vivo.
Materials and Methods
stuDy suBJeCts anD liVeR 
samples
Liver samples at diagnosis (n  =  91) were col-
lected from 40, 19, and 24 patients with AIH, hep-
atitis B virus, and nonalcoholic fatty liver disease 
(NAFLD), respectively. We also included 8 healthy 
controls (HCs). Notably, the patients who were diag-
nosed with AIH were confirmed using the simpli-
fied scoring system for AIH that was proposed by 
the International Autoimmune Hepatitis Group in 
2008.(20) The patients diagnosed with chronic hepa-
titis B (CHB) and NAFLD met the standard criteria 
of CHB and NAFLD.(21,22) For the immunohisto-
chemistry (IHC) study, liver samples from patients 
with AIH, CHB, and NAFLD were collected from 
ultrasound- guided needle liver biopsies; the eight HC 
liver samples were derived from explant donors before 
liver transplantation. Clinical characteristics of the 91 
subjects are noted in Table 1. All participants were 
enrolled in Shanghai Renji Hospital and provided 
written informed consent. The study was carried out 
under the principles of the declaration of Helsinki and 
approved by the ethics committees of Renji Hospital.
miCe
Female C57BL/6J mice were procured from the 
Shanghai Laboratory Animal Center. MTH1 loxP mice 
were bred by GemPharmatech Co., Ltd. The clusters of 
differentiation (CD)4 cre mice were kindly provided by 
Professor Nan Shen (Renji Hospital). All mice used in 
this study were 6- 8 weeks old and were contained in 
specific pathogen- free conditions in the animal facility 
of Renji Hospital, School of Medicine, Shanghai Jiao 
Tong University, Shanghai, China. All animal experi-
ments were carried out following recommendations 
from the Guide for the Care and Use of Laboratory 
Animals, Ethics Committee of Renji Hospital.
iHC staining
Formalin- fixed, paraffin- embedded tissue sections 
from liver biopsies were verified using IHC and confocal 
laser scanning microscopy experiments, as described.(23) 
Briefly, after antigen retrieval, liver samples were incu-
bated with goat serum for 30 minutes before they were 
incubated with primary antibody MTH1 (ab200832; 
Abcam) at 4°C overnight. After three washes with 
phosphate- buffered saline (PBS), the slides were incu-
bated with a horseradish peroxidase- conjugated sec-
ondary antibody for IHC at room temperature for 30 
minutes. Liver sections were blindly evaluated by two 
pathologists. The expression of MTH1 was scored on a 
0- 4- point scale per high- power field. Cases were scored 
taBle 1. CHaRaCteRistiCs oF patients WitH aiH, CHB, oR naFlD anD HCs.
AIH (n = 40) CHB (n = 19) NAFLD (n = 24) HC (n = 8)
Age (years) 51.80 ± 1.626 39.95 ± 2.087 45.75 ± 2.484 30.63 ± 1.908
Sex (F/M) 37/3 6/13 14/10 4/4
ALT (U/L) 141.2 ± 21.30 57.22 ± 30.46 94.13 ± 17.07 21.63 ± 2.521
AST (U/L) 142.7 ± 24.44 38.46 ± 11.72 52.63 ± 6.980 18.75 ± 1.319
ALP (U/L) 115.1 ± 14.02 72.42 ± 4.841 98.50 ± 8.458 83.25 ± 6.038
GGT (U/L) 112.3 ± 19.90 25.66 ± 4.938 154.0 ± 64.65 18.38 ± 2.322
TBIL (μmol/L) 21.29 ± 2.614 14.25 ± 1.768 16.14 ± 2.276 10.10 ± 1.196
IgG (g/L) 15.70 ± 0.6543 12.48 ± 1.156 13.87 ± 0.9054 NA
Continuous data are shown as mean ± SEM.
Abbreviations: F/M, female/male; IgG, immunoglobulin; NA, not applicable; TBIL, total bilirubin.
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as follows: 1 if expression area <25%, 2 if ≥25%- 50%, 3 
if ≥50%- 75%, and 4 if ≥75%.
ConFoCal staining
Confocal laser scanning microscopy was used for the 
detection of costaining markers, as described.(24) Briefly, 
after antigen retrieval, liver samples were incubated with 
donkey serum for 30 minutes before being incubated 
with primary antibodies MTH1 (ab200832; Abcam), 
CD3 (60181- 1- Ig; Proteintech), CD4 (ab67001; 
Abcam), and CD8 (ab17147; Abcam) at 4°C overnight. 
After three washes with PBS, the slides were incu-
bated with fluorochrome- conjugated secondary anti-
bodies (1:200; Invitrogen) at room temperature for 30 
minutes. Consequently, the nucleus was stained using 
4´,6- diamidino- 2- phenylindole (Southern Biotech, 
Birmingham, AL). Histologic immunofluorescence was 
determined using an LSM 710 laser scanning confocal 
microscope (Carl Zeiss, Jena, Germany).
statistiCal analysis
Data were analyzed using GraphPad Prism 6 
software. All values were expressed as mean ±  SEM. 
Statistical differences for normally distributed data 
were analyzed by the Student t test. Correlations 
were determined by Spearman’s rank correlation coef-
ficient for nonparametric data or Pearson’s correla-
tion coefficient for normally distributed data. In all 
tests, P < 0.05 was considered statistically significant. 
Details on other materials and methods are provided 
in the Supporting Materials.
Results
inCReaseD eXpRession oF 
mtH1 in liVeRs oF patients 
WitH aiH
The hypothesis is that MTH1 could be needed 
for activated T cells to detoxify the deoxyribonu-
cleoside triphosphate (dNTP) pools to maintain 
genome integrity during proliferation. Therefore, 
we used IHC to examine MTH1 protein expres-
sion in the liver from patients with AIH, CHB, or 
NAFLD and from HCs. We found that MTH1 was 
predominantly located in immune cells whereas the 
hepatocytes barely expressed MTH1 in the three 
diseases or HCs. Moreover, there was a significantly 
increased abundance of MTH1- positive cells in 
AIH compared to either HCs (P  <  0.01) or CHB 
and NAFLD (both P < 0.0001), as illustrated in Fig. 
1A,B. Notably, MTH1 expression was positively 
correlated with degrees of inflammation (r = 0.6989, 
P < 0.0001) other than the different stages of fibro-
sis (r = 0.3119, P = 0.0725) in AIH, as shown in Fig. 
1C. The expression of MTH1 was positively cor-
related with serum levels of alanine aminotransferase 
(ALT) (r  =  0.6467, P  <  0.0001), aspartate amino-
transferase (AST) (r  =  0.3534, P  =  0.0404), alka-
line phosphatase (ALP) (r  =  0.4657, P  =  0.0063), 
and gamma- glutamyltransferase (GGT) (r  =  0.52, 
P  =  0.0016) (Fig. 1D,E). In summary, the above 
results suggest that MTH1 is highly expressed in 
AIH and positively correlated with disease severity.
inCReaseD eXpRession oF 
mtH1 in HepatiC t Cells oF 
patients WitH aiH
To identify the cellular source of MTH1 in 
patients with AIH, we conducted an immunofluo-
rescence double- staining assay for MTH1 and CD3, 
CD4, and CD8 and found there were plentiful T 
cells that were colocalized with MTH1 in AIH (Fig. 
2A; Supporting Fig. S1A,B). Similarly, the number 
of MTH1+CD3+ T cells was positively correlated 
with the degree of hepatic inflammation (r = 0.8115, 
P  <  0.0001) but not with the different stages of 
fibrosis (r  =  0.1160, P  =  0.5980) in patients with 
AIH (Fig. 2B). Additionally, positive correlations 
were found between numbers of MTH1+CD3+ 
T cells and the serum levels of ALT (r  =  0.7008, 
P  =  0.0002), AST (r  =  0.6862, P  =  0.0003), ALP 
(r  =  0.7128, P  =  0.0001), and GGT (r  =  0.6853, 
P  =  0.0004) (Fig. 2C,D). In summary, the above 
results suggest that MTH1 is highly expressed in T 
cells and the numbers of MTH1+CD3+ T cells are 
related to the disease severity of AIH.
eFFeCt oF mtH1 on 
aCtiVation anD FunCtion oF 
Human t Cells IN VITRO
To assess the expression of MTH1 on T cells, 
CD3+ T cells isolated from healthy human volun-
teers were first treated with or without anti- CD3/
Hepatology CommuniCations, Vol. 0, no. 0, 2021 CHen, Hua, et al.
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Fig. 1. Increased expression of MTH1 in livers of patients with AIH. (A,B) Representative IHC staining (magnification ×400) and 
statistical analysis of hepatic MTH1 expression in HCs (n = 8), HBV (n = 19), NAFLD (n = 24), and AIH (n = 34). Scale bar, 50 μm. (C) 
Degree of hepatic MTH1+ cells was positively correlated to the degree of hepatic inflammation but showed no difference among advanced 
fibrosis stages. (D) Degree of hepatic MTH1+ cells in portal areas was positively correlated with serum disease activity biomarkers ALT 
and AST in patients with AIH. (E) There was a positive correlation of the degree of hepatic MTH1+ cells with levels of serum ALP and 
GGT. Bars reflect the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviation: HBV, hepatitis B virus.
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CD28 beads for 72 hours. We found that activated T 
cells had an increased expression of MTH1 compared 
to resting T cells (Fig. 3A). To fully elucidate the 
impact of MTH1 on T cells, we stimulated CD3+ T 
cells from healthy human volunteers with anti- CD3/
CD28 beads for 72 hours with or without karonudib. 
Compared to the vehicle controls, the percentage of 
activated T cells (characterized by CD25+ or CD69+) 
was significantly decreased by karonudib treatment 
(Fig. 3B,C). We further tested the effect of karonu-
dib on T- cell subsets. We found that karonudib had 
an evident inhibitory effect on proinflammatory cells, 
such as T helper 1 (Th1) cells, CD4+ T cells express-
ing tumor necrosis factor alpha (TNF- α), and CD8+ 
T cells expressing interferon- gamma (IFN- γ) and 
TNF- α (Supporting Fig. S2A,B). However, karonu-
dib had no inhibitory effect on T regulatory (Treg) 
cells and Th17 cells (Supporting Fig. S2A). Another 
interesting finding is that karonudib did not change 
the number of resting T cells. However, the number of 
activated T cells decreased significantly when treated 
with karonudib (Fig. 3D). Therefore, we further 
conducted cell- trace proliferation assays to examine 
whether karonudib had an antiproliferative property. 
Intriguingly, the administration of karonudib robustly 
inhibited both CD4 and CD8 T- cell proliferation 
derived from both HCs and patients with AIH who 
were treatment naive (Fig. 3E). We also observed 
Fig. 2. Hepatic MTH1+CD3+ T cells correlated with disease activity in AIH. (A) Representative confocal staining of CD3 (red), 
MTH1 (green), and DAPI (for nuclei in blue) (magnification ×400) in the liver of patients with AIH. Scale bar, 20 μm. (B) Number of 
MTH1+CD3+ T cells in portal areas was positively correlated with degree of hepatic inflammation but showed no clear link with fibrosis 
stages in AIH. (C) Number of MTH1+CD3+ T cells in portal areas had a significant positive correlation with levels of serum ALT and 
AST in patients with AIH. (D) Number of MTH1+CD3+ T cells in portal areas was positively correlated with levels of serum ALP and 
GGT. Bars reflect the mean ± SEM. Abbreviations: DAPI, 4 0, 6- diamidino- 2- phenylindole; hpf, high- power field.
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Fig. 3. Karonudib significantly inhibited T- cell proliferation in human T cells in vitro. Isolated human CD3+ T cells were cultured 
with/without anti- CD3/CD28 beads for 72 hours. Representative western blot analyses of MTH1 72 hours after anti- CD3/CD28 
beads stimulation. (B,C) Isolated T cells were activated with anti- CD3/CD28 beads with or without 2 μM karonudib for 72 hours. 
The percentage of CD25+ and CD69+ T cells was determined on day 3 by flow cytometry. (D) Analysis of T- cell number treated with 
karonudib for 72 hours after anti- CD3/CD28 beads stimulation. (E) Statistical analysis of the T- cell proliferation assay treated with/
without 2 μM karonudib for 72 hours from HCs and patients with AIH who were treatment naive. (F) Representative western blot 
analyses of P53, P21, P27, CDK2, and cyclin E 72 hours after anti- CD3/CD28 beads stimulation. The GAPDH blot was used as a 
loading control. Data are from one experimental representative of at least three independent experiments and represent triplicate wells. 
Bars reflect the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, 
glyceraldehyde 3- phosphate dehydrogenase.
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that the expression of proteins that facilitated the cell 
cycle, such as cyclin E and cyclin- dependent kinase 
2 (CDK2), were inhibited, whereas the expression of 
proteins, such as P53, P21, and P27, that limited the 
speed of the cell cycle were significantly up- regulated 
(Fig. 3F).
Studies showed that activation of protein kinase 
B (AKT), nuclear factor kappa B (NF- κB), and 
extracellular signal- regulated kinase (ERK) path-
ways are closely associated with T- cell activation 
and proliferation.(25- 27) Our study showed that the 
phosphorylated proteins of AKT and P65 were 
strongly inhibited by karonudib (Supporting Fig. 
S3A,B), while the expression of the phosphorylated 
proteins of ERK pathways remained unchanged 
(Supporting Fig. S3C). Because Th1 cells play an 
important role in AIH, we next sought to define 
whether the MTH1 inhibitor can modulate the dif-
ferentiation of Th1 in an in vitro setup. Remarkably, 
compared to the vehicle controls, the percentage of 
CD4+ T cells expressing IFN- γ was significantly 
lower (Supporting Fig. S4A). Collectively, our data 
suggest that the treatment using karonudib reduced 
human T- cell activation and function in vitro.
KaRonuDiB inCReaseD Dna 
Damage in aCtiVateD Human t 
Cells IN VITRO
The traditional role of MTH1 is to hydrolyze oxi-
dized dNTPs into deoxyribonucleoside monophos-
phates to prevent the incorporation of oxidative DNA 
damage.(15) Previous studies have verified that sev-
eral MTH1 inhibitors prevent DNA damage repair, 
inducing DNA damage and cytotoxicity in cancer 
cells.(18,19) The comet assay detected that activated 
T cells treated with karonudib for 72 hours showed 
evident comet tails, which suggested significant DNA 
damage (Fig. 4A,B). Subsequently, we determined 
the levels of proteins of two classic markers of DNA 
damage, phosphorylated histone H2AX (γ- H2AX) 
and cleaved poly(adenosine diphosphate ribose) poly-
merase (PARP), using western blot. The expression 
of these markers was elevated when the activated T 
cells were treated with karonudib (Fig. 4C). Another 
interesting finding was that the proapoptotic property 
of karonudib worked selectively on activated cells and 
lacked obvious proapoptotic effects on the resting T 
cells (Fig. 4D,E). Therefore, these results imply that 
karonudib could increase the extent of DNA damage 
specifically in activated T cells.
speCiFiC Deletion oF mtH1 
in t Cells inHiBiteD Con 
a- inDuCeD Hepatitis By 
DeCReasing aCtiVation oF 
HepatiC t Cells
To verify the role of MTH1 in experimental T- cell- 
mediated hepatitis, our study developed mice with a 
T- cell- specific deletion of MTH1 by breeding the 
MTH1loxP/loxP mice and the CD4- cre strain. Because 
mature CD4+ and CD8+ T cells in the periphery 
develop from double- positive T cells, the expression of 
Cre under the control of CD4 deletes LoxP- flanked 
genes in both CD4+ and CD8+T cells.(28) The specific 
deficiency of MTH1 in T cells alone could rescue Con 
A- induced hepatitis to a great extent, and this was 
indicated by the sharp decline in the levels of serum 
ALT and AST (Fig. 5A). Histologic assessment of 
liver tissues reaffirmed the amelioration of liver injury 
in CD4creMTH1loxP/loxP (MTH1 knockout [KO]) 
mice, which was revealed by a narrowed area of hepatic 
necrosis (Fig. 5B). Moreover, MTH1 KO mice that 
were tail- vein injected with Con A had a remarkably 
decreased level of inflammatory mediators compared 
to that of wild- type (WT) mice that received a similar 
treatment (Fig. 5C). Therefore, these data imply that 
specific deletion of MTH1 in T cells alone can protect 
mice from Con A- induced liver injury.
Because T cells play a critical role in the pathogen-
esis of Con A- induced hepatitis, we further explored 
the effects of MTH1 on T cells in mice. We tested 
T- cell activation markers (CD25 and CD69) and 
naive T- cell markers (CD44 and CD62L) in lym-
phocytes of both liver and spleen by using MTH1 
KO mice. We found that the proportion of CD25+ T 
cells markedly decreased in both the liver and spleen 
of these mice when compared to model mice (Fig. 
6A,B). We also observed a similar trend of CD69+ 
T cells in both liver and spleen of MTH1 KO mice 
(Fig. 6C,D). Additionally, the proportion of naive T 
cells was increased in both liver and spleen of MTH1 
KO mice when compared to model mice (Fig. 6E,F). 
We further tested whether specific deletion of MTH1 
in T cells had any effect on T- cell subsets in the Con 
Hepatology CommuniCations, Vol. 0, no. 0, 2021 CHen, Hua, et al.
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Fig. 4. Karonudib rendered activated T cells more susceptible to DNA damage in vitro. (A) Representative fields corresponding to each 
treatment were photographed. Isolated human T cells were activated with/without anti- CD3/CD28 beads in the presence of DMSO 
or 2 μM karonudib for 72 hours. The alkaline comet assay was conducted and nucleoids were visualized by epifluorescence microscopy 
using a fluorescein isothiocyanate filter. (B) Quantification of comet tail moment. Values represent mean ± SEM from three independent 
experiments (100 comets per experiment). (C) Levels of cleaved- PARP and phosphorylated histone H2AX (γ- H2AX) were determined 
by immunoblot analysis. The GAPDH blot was used as a loading control. (D,E) Intracellular flow cytometry assessment of annexin V 
and propidium iodide expression in anti- CD3/CD28 beads- stimulated CD4+ and CD8+ T lymphocytes treated with 2 μM karonudib 
or DMSO after 72 hours. Data are from one experimental representative of at least three independent experiments. Bars reflect the 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 
3- phosphate dehydrogenase.
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A model. We found that MTH1 KO mice had a 
decreased level of IFN- γ in both CD4+ and CD8+ 
T cells (Fig. 6G,J). However, no differences were 
found for Treg cells and Th17 cells between MTH1 
KO mice and WT mice (Fig. 6H,I). In addition, 
evident inhibition of T- cell proliferation was observed 
in MTH1 KO mice, as shown in Fig. 6K. Taken 
together, our findings showed that the specific defi-
ciency of MTH1 in T cells inhibited the activation 
and proliferation of T cells in mice.
Fig. 5. Target deletion of MTH1 in T cells protected from Con A- induced liver injury. (A) Serum levels of ALT and AST were 
assessed at 24 hours following Con A (8 mg/kg) injection. (B) Histologic analysis of mouse livers was performed using hematoxylin and 
eosin staining (magnification ×400; scale bar, 50 μm) 24 hours after Con A injection (8 mg/kg). (C) Con A- induced elevation of serum 
inflammatory cytokines was ameliorated in MTH1 KO mice. Results represent the mean ± SEM (n = 4- 6 mice per group). *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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Fig. 6. Specific deletion of MTH1 in T cells inhibited Con A- induced hepatitis by decreasing the activation of hepatic T cells. (A,B) 
Frequency of CD25+ cells in hepatic and splenic CD4+ T and CD8+ T cells are shown. (C,D) Frequency of CD69+ cells in hepatic and 
splenic CD4+ T and CD8+ T cells are shown. (E,F) Frequency of naive cells (CD44- CD62L+) in hepatic and splenic CD4+ T and CD8+ 
T cells are shown. (G- I) Summary graphs of (G) IFN- γ+, (H) IL- 17+, and (I) CD25+FoxP3+ in hepatic CD4+ T cells. ( J) Frequency of 
IFN- γ+ cells in hepatic CD8+ T cells. (K) Statistical analysis of the T- cell proliferation assay from T cells of WT mice and MTH1 KO 
mice for 72 hours. Data are from one experimental representative of at least three independent experiments and represent triplicate wells. 
Graphs reflect mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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mtH1 inHiBitoR KaRonuDiB 
attenuateD Con a- inDuCeD 
Hepatitis By inHiBiting t- Cell 
aCtiVation anD pRoliFeRation
To further confirm the role of MTH1 in experi-
mental T- cell- mediated hepatitis, we administrated the 
MTH1 inhibitor karonudib to a Con A- induced liver 
injury murine model. Mice administered with karonudib 
were completely protected from Con A- induced liver 
injury, which was demonstrated by the sharp decrease 
in serum ALT and AST levels when compared to Con 
A- treated mice without any karonudib administration 
(placebo group) (Fig. 7A). Through histologic studies, 
karonudib significantly alleviated the degree of necrosis 
compared to the placebo group (Fig. 7B). Additionally, 
the administration of karonudib significantly decreased 
serum levels of proinflammatory cytokines, such as 
interleukin (IL)- 6, IFN- γ, and TNF- α, in the Con 
A- induced hepatitis model (Fig. 7C). Taken together, 
these results suggest that karonudib treatment could be 
efficient in treating Con A- induced hepatitis.
Similar to the results of MTH1 KO mice, the 
proportion of CD25+ cells among CD4+ or CD8+ 
T cells from karonudib- treated mice was significantly 
decreased compared to the placebo group (Fig. 8A,B). 
Karonudib also inhibited the expression of CD69 in 
T cells of the liver and spleen from Con A- treated 
mice (Fig. 8C,D). In addition, the proportion of naive 
T cells in karonudib- treated mice was significantly 
increased in both the liver and spleen, as shown in 
Fig. 8E,F. We further tested the effect of karonudib 
on T- cell subsets in the Con A model. We found that 
karonudib had an evident inhibitory effect on proin-
flammatory cytokines, such as IFN- γ, in both CD4+ 
and CD8+ T cells and a slightly decreased level of 
IL- 17 in CD4+ T cells (Fig. 8G,H,J). However, karo-
nudib had no inhibitory effect on Treg cells (Fig. 8I). 
Interestingly, there was an obvious suppression of 
mouse activated T- cell proliferation using the karo-
nudib treatment in vitro (Fig. 8K). All these results 
show that karonudib attenuated Con A- induced hep-
atitis by inhibiting T- cell activation and proliferation.
Discussion
The most striking translational finding of this study 
is that MTH1 is extensively expressed and clinically 
relevant in AIH. Karonudib and specific knockout 
of MTH1 in T cells protected the mice from Con 
A- induced liver injury. Following MTH1 inhibition, 
intrahepatic T- cell activation was suppressed and the 
proportion of naive T cells was increased. In addi-
tion, karonudib robustly decreased the levels of these 
proinflammatory mediators in activated T cells and 
inhibited Th1 differentiation. These effects are based 
on DNA damage susceptibility of the hyperactive 
T cells.
A previous study showed that DNA damage is 
detectable once the T cells have been activated.(29) 
In our study, we observed that the activated T cells 
expressed higher levels of MTH1 than the resting 
T cells to counteract the deleterious effects of DNA 
damage. Clinically, the adoption of karonudib in the 
treatment of cancer is to induce cell- cycle arrest, 
which suppresses the rapid proliferation of cancer 
cells. Hyperactive T cells and cancer cells are both 
rapid proliferating cells and have a similar meta-
bolic pattern.(30,31) Interestingly, karonudib rendered 
activated T cells more susceptible to DNA damage, 
evidenced by the comet assay and increased protein 
levels of γ- H2AX and cleaved PARP, consistent 
with a study that demonstrated MutT contributed 
to the fidelity of DNA.(32) The carboxyfluorescein 
succinimidyl ester assay also showed that karonu-
dib inhibited T- cell proliferation. Additionally, the 
expression of cyclin E and CDK2, which facilitated 
the cell cycle, were inhibited, whereas the expression 
of P21, P27, and P53, which inhibited the cell cycle, 
were enhanced. We therefore showed that the karo-
nudib inhibition property in T cells is consistent 
with the role of karonudib in cancer cells, which is 
to induce cell- cycle arrest.
The DNA damage response/repair (DDR) path-
way is well elucidated in studies of cancer biology. 
Many antitumor therapeutics exploit DNA dam-
age by overwhelming repair mechanisms to trig-
ger cancer- cell death.(33,34) Different cells have been 
armed with proper mechanisms to defend themselves 
against oxidative DNA damage caused by misin-
corporation of 8- oxoG into DNA. Among them, 
MTH1, 8- oxoguanine DNA glycosylase 1 (OGG1), 
and MutY DNA glycosylase (MUTYH) are the 
main enzymes that eliminate the devastating effects 
caused by 8- oxoG.(35- 37) Mainly, MTH1 works in the 
nucleotide pool and depletes 8- oxoG by hydrolyz-
ing 8- oxo- dGTP to 8- oxo- dGMP at the source.(38) 
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OGG1 minimizes any potential genotoxicity by 
excising the opposite cytosine of 8- oxoG from DNA 
strands.(39) The MUTYH enzyme removes the adenine 
that pairs with 8- oxoG.(37) In short, the overall role of 
the three enzymes is to minimize the serious conse-
quences caused by an increased cellular accumulation 
Fig. 7. Karonudib significantly attenuated Con A- induced liver injury. (A) Serum of ALT and AST levels at 24 hours in Con A (10 
mg/kg)- treated mice that were administered simultaneously with/without karonudib by gavage. (B) Representative hematoxylin and 
eosin staining (magnification ×400) of liver tissues from mice treated with Con A for 24 hours; scale bar, 50 μm. Extensive necrosis 
in hepatocytes was observed in Con A- treated mice administered simultaneously without karonudib by gavage, while a significant 
reduction of necrosis was observed in mice administered simultaneously with karonudib by gavage. (C) Con A- induced elevation of serum 
inflammatory cytokines was ameliorated in mice treated with karonudib by gavage. Data are from one experimental representative of at 
least three independent experiments. Results represent the mean ± SEM (n = 4- 6 mice per group). *P < 0.05, ***P < 0.001, ****P < 0.0001.
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Fig. 8. Karonudib inhibited T- cell activation and increased naive T cells in mice. (A,B) Frequency of CD25+ cells in hepatic and splenic 
CD4+ T and CD8+ T cells are shown. (C,D) Frequency of CD69+ cells in hepatic and splenic CD4+ T and CD8+ T cells are shown. 
(E,F) Frequency of naive cells (CD44- CD62L+) in hepatic and splenic CD4+ T and CD8+ T cells are shown. (G- I) Summary graphs 
of (G) IFN- γ+, (H) IL- 17+, and (I) CD25+FoxP3+ in hepatic CD4+ T cells. ( J) Frequency of IFN- γ+ cells in hepatic CD8+ T cells. 
(K) Statistical analysis of the T- cell proliferation assay treated with/without 2 μM karonudib from splenic T cells of mice for 72 hours. 
Data are from one experimental representative of at least three independent experiments and represent triplicate wells. Graphs reflect 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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of 8- oxoG in cells, thus preventing mutagenesis and 
cell death.(35)
Several studies have also emphasized the import-
ant role of DDR in autoimmune diseases and other 
chronic inflammation.(40,41) Our research collabora-
tors recently identified the small- molecule inhibitor 
of OGG1, called TH5487, and found it hampered 
OGG1 binding to the G- rich regions adjacent to 
NF- κB binding sites in promoters of proinflamma-
tory genes. TH5487 robustly inhibits the inflamma-
tory response in cultured lung epithelial cells in vitro 
and inhibits TNF- α- induced neutrophilic inflamma-
tion in vivo.(42)
Currently, the mainstay of treatment for AIH is the 
use of prednisone, which induces inflammation remis-
sion, and the combination of prednisone and azathio-
prine to maintain therapeutic efficacy. Different drugs 
have been developed to treat AIH; however, they 
have not been satisfactory in clinical practice as they 
had different side effects, such as myelosuppression 
and infection.(8) Karonudib, as the latest generation 
of MTH1 inhibitors, has much better oral availabil-
ity and displays good pharmacokinetic properties.(18) 
Similar to the use of a small- molecule inhibitor of 
OGG1 on suppressing inflammation, the adoption of 
karonudib as the potential treatment of AIH is novel 
because this therapy makes full use of distinct aspects 
of T- cell biology in the persistent inflammatory envi-
ronment. Notably, the high degree of susceptibility 
that hyperactive T cells displayed relative to resting 
T cells after they were treated with karonudib could 
cause minimal damage to reservoir T cells that are 
vital in other physiological processes, such as preven-
tion of infection and cancer, hopefully bringing more 
potential therapeutic gains with less potential toxicity.
In conclusion, our study suggests that the nucle-
otide pool enzyme MTH1 plays an essential role in 
Con A- induced liver injury as well as in the disease 
context of AIH by preventing DNA damage in acti-
vated T cells. Although MTH1 is initially rooted in 
cancer treatment, it can be applied in the treatment 
of T- cell- mediated liver injury. Therefore, the findings 
from our study have emphasized the high potential of 
the MTH1 enzyme as a novel therapeutic target in 
AIH treatment and karonudib as a novel and promis-
ing drug for patients with AIH.
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